Compare Estee Lauder Companies Inc (EL) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs Tempus AI — how do they compare? Estee Lauder Companies Inc trades at $93.37 (market cap $34.22B), while Tempus AI trades at $70.5 (market cap $12.77B). The key difference: Estee Lauder Companies Inc is far larger — about 2.7× Tempus AI's market cap, and Estee Lauder Companies Inc pays a 1.48% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold Estee Lauder Companies Inc for 122 Days and Tempus AI for 22 Days on average.
| EL | TEM | |
|---|---|---|
Market Cap | $34.22B | $12.77B |
Volume | 2,303,792 | 8,980,490 |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $119.61 | $99.28 |
52-Week Low | $67.23 | $41.55 |
Typical Hold Time | 122 Days | 22 Days |
Enterprise Value | $39.97B | $13.40B |
Dividend Yield | 1.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Estée Lauder (EL) trades at $94.32, up 1.03% today, with a bullish technical signal from moving averages and recent earnings beats. The company reported a net loss of $1.13 billion in 2025 despite a high gross margin of 75.5%, while 2026 forecasts show a return to profitability. Analysts maintain a consensus buy rating with a $103 price target, supported by strategic partnerships in AI and leadership changes aimed at driving growth.
The stock's outlook is cautiously optimistic, with earnings recovery and digital initiatives offering upside, but high debt levels and margin pressures pose risks. Investor sentiment is mixed amid volatile cash flows and competitive headwinds in the beauty sector.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
